Nuclear Medicine Market

Nuclear Medicine Market – Size, Share, Growth, Trends, and Forecast (2025–2034): Global Industry Analysis by Product Type (Diagnostics: SPECT, PET, Others; Therapeutics: Alpha Emitters, Beta Emitters, Brachytherapy), Application, End User, and Region

Published Date: November - 2025 | Publisher: MRA | No of Pages: 250 | Industry: Healthcare | Format:

Nuclear Medicine Market Summary

The global nuclear medicine market is undergoing rapid innovation driven by rising chronic disease prevalence, expanding use of hybrid imaging systems, and continuous technological advancements in diagnostic and therapeutic radiopharmaceuticals.

Key highlights of the global nuclear medicine market include

Market Value (2024) US$ 18.6 Bn – Supported by technological progress and growing diagnostics demand.
Forecast Period 2025–2034 – Strong expansion led by hybrid imaging and precision medicine.
Expected CAGR 10.8% – Reflecting sustained adoption in clinical diagnostics.
Forecast Value (2034) US$ 57.3 Bn – Driven by advancements in radiopharmaceuticals and early disease detection.

Expert Insights and Strategic Outlook

The nuclear medicine industry is experiencing exceptional growth due to advancements in PET and SPECT imaging, increasing prevalence of cancer and cardiovascular diseases, and rising emphasis on early-stage diagnostics. As healthcare systems globally shift toward precision medicine, nuclear imaging delivers unparalleled insights into metabolic and cellular activity, enabling faster and more accurate diagnosis than conventional imaging.

Continuous development in radiopharmaceuticals, including new isotopes for both diagnostics and therapy, is expanding clinical applications. Targeted radionuclide therapies are transforming cancer care by enabling selective destruction of malignant cells while minimizing damage to healthy tissues.

Despite strong momentum, challenges such as high procedural costs, regulatory complexity, and isotope shortages affect market performance. However, expanding research initiatives, favorable reimbursement policies, and increasing government support for isotope production are expected to strengthen market growth through 2034.

Market Overview

Nuclear medicine refers to a specialized medical imaging field that uses radioactive materials (radiopharmaceuticals) to visualize organ functions and diagnose or treat diseases. It provides metabolic and physiological information that traditional imaging methods cannot detect, making it essential for early detection of cancerous, neurological, and cardiovascular conditions.

Common nuclear medicine modalities include

SPECT (Single Photon Emission Computed Tomography)
PET (Positron Emission Tomography)
Both methods are non-invasive, highly sensitive, and crucial for evaluating disease progression, treatment response, and recurrence.

Beyond diagnosis, nuclear medicine plays a key role in targeted radionuclide therapy, offering precise treatment options for various cancers, including thyroid, prostate, and neuroendocrine tumors. Ongoing advancements in imaging, AI integration, and isotope development continue to shape the market’s future, supporting personalized treatment plans and improved patient outcomes.

Key Market Drivers

Attribute	Detail
Market Growth Drivers	Growing Adoption of Hybrid Imaging Systems; Increased Demand for Early and Accurate Diagnosis

Growing Adoption of Hybrid Imaging Systems Driving Market Size

Hybrid imaging systems such as PET/CT and SPECT/CT combine anatomical and functional data into a single scan, significantly improving diagnostic accuracy. These systems allow clinicians to localize disease precisely and plan treatment more effectively.

Their value extends across oncology, cardiology, and neurology due to superior image detail, improved workflow efficiency, and reduced radiation exposure. Healthcare facilities are increasingly investing in these advanced systems, resulting in strong growth in nuclear imaging adoption.

As technological innovation continues, hybrid imaging remains a cornerstone of nuclear medicine’s expansion, offering enhanced patient care and diagnostic precision.

Increased Demand for Early and Accurate Diagnosis Bolstering Market Growth

The demand for early detection of cancer, cardiovascular diseases, neurological disorders, and endocrine abnormalities is increasing worldwide. Nuclear medicine provides a powerful method to detect metabolic changes before structural changes occur, enabling better treatment outcomes.

A growing geriatric population, which is more prone to chronic diseases, further boosts the demand for nuclear diagnostic procedures. Technological advancements in PET and SPECT imaging and new radiopharmaceuticals are strengthening the utility and adoption of nuclear medicine in early disease diagnosis.

As precision healthcare gains global traction, nuclear medicine is set to play a central role in personalized patient management and risk prediction.

Diagnostics Product Type Leading the Nuclear Medicine Market

Diagnostic radiopharmaceuticals and imaging systems dominate the nuclear medicine market. PET and SPECT technologies are essential for detecting cancer, cardiac disorders, neurological diseases, and metabolic conditions.

Advancements include enhanced image resolution, shorter scan times, and improved patient safety. The strong demand for early disease detection and preventive healthcare is increasing usage of diagnostic nuclear procedures.

Patient awareness regarding early cancer screening, improved accessibility of imaging centers, and technology integration into healthcare workflows continue to push diagnostic products to the forefront of the global market.

Regional Outlook

Global Nuclear Medicine Market – Regional Analysis

Attribute	Detail
Leading Region	North America

North America holds the largest market share due to its advanced healthcare infrastructure, robust research capabilities, and strong focus on early diagnosis. The region's higher adoption of hybrid imaging systems and strong presence of leading radiopharmaceutical manufacturers further strengthen its leadership.

Supportive reimbursement structures, extensive clinical use of PET/CT and SPECT/CT systems, and growing investment in isotope production contribute significantly to market expansion.

Competitive Landscape

Major companies in the nuclear medicine market are actively expanding product portfolios, enhancing imaging precision, and investing in advanced radiopharmaceutical technologies. Strategic collaborations, acquisitions, and R&D initiatives form the core of competitive activity.

Prominent Companies Operating in the Global Market

Cardinal Health
Jubilant Pharma Company
The Bracco Group
Nordion (Canada) Inc.
NTP Radioisotopes SOC Ltd.
ECZACIBAŞI-MONROL
Lantheus
China Isotope & Radiation Corporation
Eckert & Ziegler Medical
Mallinckrodt plc
GE HealthCare
Blue Earth Diagnostics
NorthStar Medical Radioisotopes, LLC
B. J. Madan & Co
Curium Pharma
Novartis AG
Bayer AG
Other emerging players

Key Developments in the Market

June 2025 GE HealthCare received FDA approval for the updated Vizamyl PET imaging agent label for beta-amyloid detection, expanding its clinical use and improving quantitative assessment for Alzheimer’s diagnosis.
March 2025 Actinium Pharmaceuticals introduced ATNM-400, a first-in-class radiotherapy targeting a non-PSMA marker for prostate cancer, addressing unmet needs in patients resistant to conventional therapies.

Nuclear Medicine Market Snapshot

Attribute	Detail
Size in 2024	US$ 18.6 Bn
Forecast Value (2034)	US$ 57.3 Bn
CAGR (2025–2034)	10.8%
Historical Data	2020–2023
Quantitative Units	US$ Bn
Analysis Scope	Includes segment analysis, regional insights, drivers, restraints, opportunities, trends, and value chain assessment
Competition Landscape	Includes competitive matrix, company profiles, strategies, and key financials
Format	Electronic (PDF) + Excel